Boehringer Ingelheim Animal Health (BI) announced the recipients of the 2021 Advancement in Equine Research Awards at the American Association of Equine Practitioners Annual Convention in Nashville, Tennessee. The recipients were chosen based on their research proposals focused on equine infectious respiratory disease and equine asthma syndrome.
Recipients include the following:
- Mathilde Leclere, DVM, PhD, DACVIM and Berta Mozo, DVM (resident), University of Montreal, St-Hyacinthe, Qubec, Canada
- Angela Bordin, Med Vet, MS, PhD and Bibiana Petri da Silveira, MS (graduate student), Texas A&M University, College Station, Texas
- Nicola Pusterla, DVM, PhD, DACVIM, DAVDC, University of California Davis, Davis, California
- Kelsey Hart, DVM, PhD, DACVIM and Londa J. Berghaus, MS (graduate student), University of Georgia, Athens, GA
Each award recipient will receive a minimum of $15,000 in support of their research.
Since 2011, Boehringer Ingelheim has given nearly $700,000 toward advancing the knowledge of equine disease, including the $75,000 in grants being awarded this year.
“Boehringer Ingelheim is committed to advocating for the health and well-being of horses, and as a global leader in equine health, we are dedicated to helping advance equine health care to the highest level possible,” said Steve Grubbs, DVM, PhD, DACVIM, equine technical manager for BI. “We have seen previous recipients make great advancements in equine asthma and respiratory conditions and we are confident that the work of this year’s recipients will be just as ground-breaking.”
Veterinarians, diagnosticians, and public and private researchers in the United States, Canada and Mexico were eligible to submit proposals.
For more information about the Advancement in Equine Research Awards, visit this page.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier, too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment guides us every day. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals, and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second-largest animal health business in the world, with net sales of $4.7 billion (4.1 billion euros) in 2020 and presence in more than 150 countries.
Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, with around 52,000 employees, we create value through innovation daily for our three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
In 2020, Boehringer Ingelheim achieved net sales of around $22.33 billion (19.57 billion euros). Our significant investment of over $4.2 billion (3.7 billion euros) in 2020 (18.9 percent of net sales) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
